Genome profile of human rectal tumors and response to neoadjuvant chemoradiotherapy

ABSTRACT: Background: Neoadjuvant chemoradiotherapy (NCRT) is the treatment of choice in advanced rectal cancer, even though there are many patients who will not benefit from it. There are still no effective methods for predicting which patients will respond or not. The present study aimed to define the genomic profile of rectal tumors and to identify alterations that are predictive of response in order to optimize therapeutic strategies. Methods: Forty-eight candidates for NCRT were recruited and their pretherapy biopsies analyzed by array Comparative Genomic Hybridization (aCGH). Pathologic response was evaluated by tumor regression grade (TRG).Results: Both Smoothing and Hidden Markov Model (HMM) approaches identified similar alterations, with a prevalence of DNA gains. Non responsive patients

ORGANISM(S): Homo sapiens

SUBMITTER: Chiara Molinari 

PROVIDER: E-GEOD-25885 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress